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Abstract
Background: Maternal-infant transmission of hepatitis B virus(HBV) occurs even after passive-active immunization.
Some scholars speculate that in-utero infection may be the main cause of immunoprophylaxis failure. However,
there is a lack of evidence about the possible occurrence periods of perinatal transmission.
Methods: From 2008 to 2012, 428 pairs of HBsAg-positive mothers and neonates were enrolled and 385 infants
aged 8–12 months were followed. HBV markers (HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, HBV-DNA) were
performed on all subjects.
Results: Of mothers who were positive for HBsAg, HBeAg, HBV-DNA, 35.1 %, 94.3 %, 12.7 % of their neonates were
positive for those indices, respectively. Neonates’ mean titers of those indices were significantly lower than their
mothers’. There were no significant differences in rates of positivity and mean titers of anti-HBe and anti-HBc
between neonates and mothers. Most of the positive indices turned negative during the follow-up period.
Immunoprophylaxis failed in seventeen infants: four infants had HBV-DNA > 6 log 10copies/mL both at birth and
in follow-up; in six infants, mean viral load was 3.72 ± 0.17 log 10copies/mLat birth and 7.62 ± 0.14 log 10copies/
mL at follow-up; seven infants were HBV-DNA negative at birth but were found to have > 6 log 10copies/mL
during follow-up. Infants that were immunoprophylaxis failures were all born to HBeAg-positive mothers with
HBV-DNA > 6 log 10copies/mL.
Conclusions: The placental barrier can partly prevent maternal HBsAg, HBeAg, HBV-DNA from passing through
to fetus. Performing HBsAg, HBeAg, HBV-DNA once at birth can neither diagnose nor exclude maternal-infant
transmission. The diagnosis of infection period depends on the dynamic changes in viral load from birth through
the follow-up period but whether the infection occurred in utero, at delivery or during the neonatal period could not
be determined.
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Background
Hepatitis B virus (HBV) infection is a major public
health problem in the world with about 2 billion people
who have been infected with HBV [1]. The World Health
Organization reported that there are an estimated 240
million chronically infected persons worldwide, particu-
larly in low-and middle-income countries, and an esti-
mated 650,000 people die annually due to the major
complications of chronic hepatitis B, cirrhosis and he-
patocellular carcinoma [2]. China is a high prevalence
area, with HBsAg seropositivity in the population reported
as 9.8 in 1992 and 7.2 % in 2006 [3]. Maternal-infant
transmission is the major route for HBV transmission and
subsequent chronic infectivity, accounting for up to 30 %
of cases [4]. Hepatitis B vaccination of newborn infants
reduces the likelihood of perinatal transmission from
HBeAg-positive mothers by 79–90 %, and the likelihood is
further reduced by adding concurrent administration
of hepatitis B immunoglobulin (HBIG), a regimen
(passive-active immunoprophylaxis) that is 85–95 %
effective in preventing development of a chronic HBV
carrierstate [5–7].
Before the initiation of vaccination programs for
newborns, three modes of transmission of HBV from
carrier mothers to infants were considered possible:
in utero, during delivery and postnatally [8, 9]. After
the implementation of passive-active immunoprophy-
laxis, the small proportion of failures are presumed to
be in those infants who are infected in utero and
already have an established infection at birth [10, 11].
These factors have led clinicians in China to conclude
that the appearance of those indices in newborns is
an indicator of intrauterine infection [12–14]. How-
ever, there is little evidence to determine whether or
not in-utero transmission of HBV is the major route of
perinatal transmission when infants have received passive-
active immunoprophylaxis or if other possible routes of
perinatal infection are more common than previously
believed.
Serological characteristics of hepatitis B markers in
neonate were used to analysis the periods of HBV
maternal-infant transmission by some scholars in
China. Umbilical cord (UC) blood drawing at delivery
is comperatively easy, timely, safe and acceptable by
parents. Some scholars considered that umbilical cord
blood might be contaminated by maternal blood, which
may lead to misleading results, and so they prefer to
femoral venous (FV) blood.
This study aimed to explore the possible occurrence
periods of HBV maternal-infant transmission by analyz-
ing the serological characteristics of hepatitis B markers
between HBsAg-carrier mothers and their infants. Fur-
ther, both the UC and FV were collected and compared
in this study.
Methods
Study population and sites
From January 2008 to December 2012, this prospective
study was conducted in Zhongnan Hospital of Wuhan
University and its peripheral hospitals (Mother and
Child hospitals of Dangyang city, Tongcheng county,
Huanggang city and Xiaonan district of Xiaogan city) in
Hubei province and in the Infectious Disease Hospital of
Taiyuan City in Shanxi province. HBsAg-carrier mothers
and their neonates were enrolled in this study; follow-up
was done when infants reached 8–12 months of age. HBV
markers (HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc
and HBV-DNA) were measured for all mothers, neonates
and during follow-up of these infants.
Women with more than twice the upper limit of nor-
mal for alanine aminotransferase or other complications
of gestation were excluded from this study. Women in-
volved in the study were not vaccinated against HBV.
All normal births were included in this study. Neo-
nates that were preterm, weighed 2500 g or less, or
had an Apgar score <8 were excluded from this study.
Caesarian sections were not a factor in inclusion or
exclusion criteria.
Sample collection
One staff member from each participating center was
trained in completion of a unified questionnaire for each
mother-infant pair, coordinating follow-up visits and
handling bio hazardous clinical samples.
Venous blood samples were obtained from pregnant
women during their second or third trimester and from
infants at birth and follow-up visits. Blood was collected
from neonates at the Infectious Disease Hospital of
Taiyuan City via FV blood prior to immunization while
neonates in Zhongnan Hospital of Wuhan University
and its peripheral hospitals in Hubei province (Mother
and Child hospitals of Dangyang city, Tongcheng county,
Huanggang city and Xiaonan district of Xiaogan city)
had venous samples collected via UC blood prior to
immunization. The volume of blood drawn was 2–3 ml
for each subject. The serum was separated within 1 h,
transferred into a 1.5 ml centrifuge tube and stored in
a – 70 °C refrigerator for HBV marker testing.
HBV immunoprophylaxis for infants
Passive and active immunization was given to neonates
born to HBsAg-carrier mothers. Within 24 h of delivery.
Each neonate was given 100 IU HBIG (Rongsheng
Pharmacy Company of Chengdu, Sichuan Province,
China) and 10 μg Hepatitis B vaccine (Yeast recombin-
ant hepatitis B vaccine of Beijing Tiantan Biological
Products Co.,LTD) by intramuscular injection. Vaccin-
ation was repeated with the same dosage at 1 and
6 months of age.
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Diagnosis of immunoprophylaxis failure
Infants aged 8–12 months with negative HBsAg,
HBeAg and HBV-DNA were considered HBV unin-
fected. Infants with positive HBsAg, HBeAg and HBV-
DNA were considered HBV infected and were consid-
ered as an immunoprophylaxis failure.
Laboratory methods
HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc were
performed by Cobas e601 analyzer, Roche, Germany in
those specimens drawn via the femoral vein while those
drawn from the umbilical vein were performed by Cobas
e411 analyzer, Roche, Germany. The normal reference
values for both analyzers were: HBsAg < 1.00 Cut-off-
index (COI), anti-HBs 0–10 IU/L, HBeAg < 1.00 COI,
anti-HBe > 1.00 COI, anti-HBc > 1.00 COI (The anti-HBc
was total core). The results of HBsAg, HBeAg, HBeAb
and HBcAb are semi-quantitative assessments and the re-
sult of anti-HBs is quantitative assessment.
The data in this study was obtained from two prov-
inces, Hubei province (central China) and Shanxi prov-
ince (northern China). To avoid detection error caused
by impaired specimen quality due to long-distance trans-
portation, the testing was performed in the two centers
respectively. Samples of UC blood were obtained in
Hubei province (in Wuhan and its peripheral cities) and
were analyzed in Zhongnan Hospital of Wuhan Univer-
sity where the instrument Cobas e411 was available.
Samples of FV blood were obtained in Shanxi province
(the Infectious Disease Hospital of Taiyuan City) and
were analyzed in the Infectious Disease Hospital of
Taiyuan City where the instrument Cobas e601 was
available. The two instruments were both produced by
Roche Diagnostics Company in Germany and were
utilized with the same testing principles.
The instrument, Cobase411 or 601, is a full-automatic
electro chemiluminescence immunoassay system. The
accuracy, precision, sensitivity and specificity are high,
and repetitive testing is not needed.
HBV-DNA was performed by using PCR-Fluorescence
detection kits for hepatitis B viral nucleotides (Shanghai
Kehua Bio-engineering Co., Ltd, China). Reference to
the instruction of the test kit, the positive level was set
as HBV-DNA ≥ 500 copies/ml.
Statistical analysis
The normal distribution of measurement data was first
tested. If data was of non-normal distribution, nonparamet-
ric tests were used for statistical calculations, expressed in
terms of the median (25 % to 75 % inter quartile range,
IQR). If the data was of normal distribution,t tests or
nonparametric tests were used, expressed as x SD or
median (25 % to 75 %IQR). SPSS 17.0 software package




Among samples meeting the requirements, 428 (FV, 301;
UC, 127) matched maternal-neonatal blood samples were
collected and 385 (90.0 %) (FV, 271; UC, 114) infants were
included in follow-up at the age of 8–12 months. Forty-
three infants were lost in follow-up because they left
their city of residence after delivery or because their
parents refused to have the child’s blood drawn. There
were no significant differences between the successful
and unsuccessful follow-up groups with regard to posi-
tive rates of HBV markers of mothers and their infants
(Table 1).
Semi-quantitative estimation of HBV markers in
HBsAg-carrier mothers and their neonates
In the 385 neonates of HBsAg-positive mothers, they
were collected by either FV blood or UC blood prior to
immunization and the infants were later available for
follow-up at the age of 8–12 months. Results suggest
that HBsAg, HBeAg and HBV-DNA could be partially
prevented from passing through the placenta but anti-
HBe and anti-HBc were frequently passed to the fetus.
Ratios of positive HBV markers, trans placental markers,
in neonates compared with their HBsAg-carrier mothers
were HBsAg, 35.1 (135/385), HBeAg, 94.3 (182/193),
HBV-DNA, 12.7 (28/220), anti-HBe, 95.6 (173/181) and
anti-HBc, 99.0 % (381/385). Neonates positive for HBeAg
were all born to HBeAg-positive mothers. The ratio for
each marker was similar in both the FV and UC groups
(Table 2). Semi-quantitative values of HBV markers in
matched mother-neonate pairs are reported in Table 3.
All the mothers and neonates at the time of birth were
negative for anti-HBs.
Table 1 HBV markers in groups of follow-up and lost to follow-
up
Items Markers Follow-up Lost to follow-up P-value
Mothers HBsAg(+) 100.0 % (385/385) 100.0 % (43/43) /
HBeAg(+) 50.1 % (193/385) 44.2 % (19/43) 0.460
HBV-DNA(+) 57.1 % (220/385) 53.5 % (23/43) 0.646
anti-HBe(+) 47.0 % (181/385) 41.9 % (18/43) 0.521
anti-HBc(+) 100.0 % (385/385) 100.0 % (43/43) /
Infants HBsAg(+) 35.1 % (135/385) 41.9 % (18/43) 0.378
HBeAg(+) 47.3 % (182/385) 44.2 % (19/43) 0.700
HBV-DNA(+) 7.3 % (28/385) 14.0 % (6/43) 0.215
anti-HBe(+) 44.9 % (173/385) 39.5 % (17/43) 0.499
anti-HBc(+) 99.0 % (381/385) 100.0 % (43/43) 1.000
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Changes in HBV markers during follow-up
Three hundred and eighty-five infants were followed up
for testing of HBV markers at 8–12 months of age
(Fig. 1). Serologic markers most likely to be lost were,
HBeAg and HBsAg followed by HBV-DNA, anti-HBe and
anti-HBc, respectively.
The loss of HBV markers among infants during
follow-up was similar in both the FV and UC groups
(Table 4). Anti-HBs were not found in any neonates
at birth. After completion of 3-dose hepatitis B vac-
cine series, 354 out of 385 (91.9 %) infants were positive
for anti-HBs (>10 IU/L). Among 368 babies without HBV
infection, 16 had inadequate anti-HBs (<10 IU/L). No
HBeAg-anti-HBe seroconversion was found.
One hundred and thirty-five out of 385 neonates were
positive for HBsAg. Among those, 98 were HBeAg posi-
tive, and 28 were positive for both HBV-DNA and HBeAg
at birth. Ten of the 28 had immunoprohylaxis failure dur-
ing follow-up; five with HBsAg positive, HBeAg positive
and HBV-DNA negative at birth had immunoprohylaxis
failure; one with HBsAg positive, HBeAg negative and
HBV-DNA negative at birth had immunoprohylaxis
failure during follow-up.
Among the 135 neonates, there was no one with HBV-
DNA positive but HBeAg negative at birth.
Two hundred and fifty out of 385 infants were nega-
tive for HBsAg. Among those, 84 were HBsAg negative,
HBeAg positive and HBV-DNA negative at birth, and one
of the 84 had immunoprohylaxis failure during follow-up
(Table 5); 165 were negative for HBsAg, HBeAg and HBV-
DNA both at birth and during follow-up.
Among infants followed-up, there was no discordance
in markers e.g. HBeAg and/or HBV-DNA positive but
HBsAg negative.
Cases of immunoprophylaxis failure
Seventeen of the 385 infants born to HBsAg positive
mothers were HBsAg, HBeAg and HBV-DNA positive
at age 8–12 months (Table 5). These infants were con-
sidered to be immunoprophylaxis failures, accounting
for 4.4 % (17/385) of all infants who received passive-
active immunization. These 17 infants were all born to
HBeAg positive mothers whose HBV-DNA were > 6
log 10copies/mL.
The immunoprophylaxis failure rate was 8.8 % (17/
193) in the group of HBeAg-positive mothers. The fail-
ure rates were 0 (0/164), 0(0/53), 9.7 (6/62), 10.3 (8/78)
and 10.7 % (3/28) in those infants born to subjects with
maternal HBV-DNA < 500 copies/ml, 2–5.99 log10copies/
ml, 6–6.99 log10copies/ml, 7–7.99 log10copies/ml and ≥8
log 10copies/ml, respectively.
Maternal HBsAg load, indicated with median (25 %,75 %
IQR), in the group of infants with HBV infection and
368 infants without HBV infection were 1351.5 (368.3,
Table 2 The counts of positive HBV markers of neonates
comparing with those of mothers
Items Source Mother(M) Neonate (N) N/M P-value
No. (+) No. (+) %
HBsAg FV 271 87 32.1 0.060
UC 114 48 42.1
HBeAg FV 141 136 96.5 0.076
UC 52 46 88.5
HBV-DNA FV 161 18 11.2 0.255
UC 59 10 16.9
anti-HBe FV 122 118 96.7 0.491
UC 59 55 93.2
anti-HBc FV 271 269 99.3 0.728
UC 114 112 98.2
Table 3 Quantitative values of HBV markers in matched mothers and neonates
Items n Mother (M) Neonate (N) P-value N/M
(Median)Median (25 %, 75 % IQR) Median (25 %, 75 % IQR)
HBsAg(+) FV 87 795.30 (340.28, 2341.25) 1.96 (1.19, 4.56) 0.000 0.002
UC 48 2834.50 (1557.75, 7907.25) 3.84 (2.15, 36.80) 0.000 0.001
HBeAg(+) FV 136 588.65 (282.33, 790.35) 41.45 (12.90, 128.71) 0.000 0.070
UC 46 1140.50 (579.08, 1536.25) 49.38 (11.83, 317.65) 0.000 0.043
HBV-DNA(+) FV 18 7.10 (6.88, 8.02) 3.0 (3.0, 3.48) 0.000 0.0001
UC 10 7.59 (6.50, 7.74) 3.84 (3.52, 4.94) 0.004 0.00018
anti-HBe(+) FV 118 0.029 (0.005, 0.069) 0.012 (0.004, 0.058) 0.073 /
UC 55 0.004 (0.003, 0.010) 0.003 (0.002, 0.010) 0.428 /
anti-HBc(+) FV 269 0.006 (0.004, 0.080) 0.006 (0.004, 0.072) 0.688 /
UC 112 0.006 (0.005, 0.007) 0.006 (0.005, 0.006) 0.144 /
HBsAg (COI), HBeAg (COI), HBVDNA( log 10copies/mL), anti-HBe (COI), anti-HBc (COI); /:mean titer was not compared between neonates and mothers because the
index was measured by competitive binding principle
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2615.5) COI and 1235.0 (162.1, 3983.0) COI. Compared
both, p = 0.747.
The 17 infants were divided into 3 groups, group 1 (a-d),
group 2 (a-f), group 3 (a-g), based on their levels of HBV-
DNA viral load at birth (Table 5).
Twenty-eight infants were positive for HBV-DNA,
HBsAg and HBeAg at birth and 18 (64.3 %) seroconvert
during the follow-up period. The mean level of HBV-
DNA was 3.48 ± 0.68 log 10copies/mL for these 18 in-
fants at birth. This indicates that these infants were
exposed to HBV in utero or during delivery and were
protected by passive-active immunization.
HBV-DNA in four cases remained positive and above
6 log 10copies/mL. The mean viral load was 6.93 ± 0.53
log 10copies/mL at birth and 8.15 ± 0.31 log 10copies/mL
at follow-up (t = −2.001, p = 0.092).
HBV-DNA levels of another six infants rose from a
lower level at birth to a higher level during follow-up.
In these infants, the mean viral load was 3.72 ± 0.17
log 10copies/mL at birth and 7.62 ± 0.14 log 10copies/mL
in follow-up (t = −17.699, p = 0.000).
Seven infants were negative for HBV-DNA at birth but
became positive in follow-up period with mean viral load
of 6.43 ± 1.15 log 10copies/mL. Six of these infants were
formula-fed and one was breast-fed after birth.
Anti-HBs antibodies were negative for those who had
immunoprophylaxis failure.
Discussion
Institution of nationwide HBV immunization has success-
fully reduced the seroprevalence of HBV in China. The
seroprevalence of HBsAg has decreased markedly from
over 8.5 % in 1992 to less than 1.0 % in 2006 among chil-
dren between the ages of one to 4 years since the Chinese
CDC recommended routine immunization with hepatitis B
vaccine [15]. Despite the implementation of immunization
measures, the maternal-infant transmission rate of HBV
was 4.4 % among all infants in this study. The immunopro-
phylaxis failure rate was noted in this study to be higher
than previously reported in published studies [16–18]. The
infants considered as immunoprophylaxis failures in this
prospective analysis were all born to HBeAg positive
mothers whose HBV-DNA were >6 log 10copies/mL. The
maternal-infant transmission rate was 8.8 % in the group
of HBeAg-positive mothers. Therefore, in this patient
population, mothers who had high levels of viremia formed
the primary grouping which HBV maternal-infant trans-
mission occurred and would therefore likely be a key popu-
lation to target in an effort to control HBV perinatal
transmission.
Epidemiological evidence has proven the existence of
HBV maternal-infant transmission but the exact mode
of transmission of infection is unclear. Due to the de-
velopment and the availability of advanced measuring
instruments, we had the ability to conduct this study
with a higher measure of accuracy than was previously
available in China.
It has been suggested that a fetus may obtain maternal
HBV markers passed through placenta [19–22]. In this
study, we determined the extent to which these HBV
markers can be passed transplacentally in clinical set-
tings. In this analysis, HBsAg positive rate of neonates
was 35.1% and neonatal titers of HBsAg were signifi-
cantly lower than those of the infants’ mothers. This
finding suggests that the majority of HBsAg, in indices
by either the transplacental rate or the amount, were not
passed through the placental barrier. Transplacental
transfer of HBeAg occurred in 94.3 % of cases, but the
concentration in neonates was 4.3–7.0 % of maternal
levels. There was little transplacental HBV-DNA trans-
fer, with the titer in neonates being approximately 0.01–
0.018 % of their mothers. The transplacental rate of anti-
HBe transference was 95.6 and 99.0 % for anti-HBc, with
Table 4 Loss of HBV markers during follow-up among infants in
FV group and UC group
Items Source At birth 8–12 months Loss of HBV
markers
P-value
n (+) n (+) %
HBsAg FV 87 10 88.5 0.863
UC 48 6 87.5
HBeAg FV 136 13 90.4 0.151
UC 46 8 82.6
HBV-DNA FV 18 6 66.7 1.000
UC 10 4 60.0
anti-HBe FV 118 20 83.1 0.297
UC 55 13 76.4
anti-HBc FV 269 134 50.2 0.105



















HBsAg HBeAg HBV-DNA Anti-HBe Anti-HBc
Fig. 1 The loss rates of HBV markers in follow-up infants. Black bars
represent at birth and white bars represent at follow-up. The loss
rates of HBV markers were: HBsAg, 88.1 %, HBeAg, 88.5 %, HBV-DNA,
64.3 %, anti-HBe, 80.9 %, anti-HBc, 47.5 %
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no significant difference in median titers between neo-
nates and their mothers. These results indicate that the
placental barrier can prevent maternal-infant transmis-
sion of HBsAg, HBeAg and HBV-DNA, but it transfers
the antibodies, anti-HBe and anti-HBc, from mother to
fetus in the vast majority of cases. This can be explained
by the fact that maternal IgG antibodies are actively
transferred through the placenta.
The capability of HBsAg, HBeAg and HBV-DNA to
pass through the placental barrier may depend upon
their molecular sizes or differences in HBV particle
morphologies [23, 24]. HBeAg is a soluble antigen with
a small molecular weight, and it easily passes through
the placenta. HBsAg, expressed on spherical or filament-
ous particles as well as Dane’s particles, passes through
the placental barrier with relative difficulty compared to
HBeAg. HBV-DNA is enveloped in a Dane particle,
which is frequently prevented from passing across the
placental barrier.
In this study, the methodology of the testing reagents
for anti-HBe and anti-HBc and the analytical instru-
mentation were designed by the competitive binding
principle, meaning a lower value indicates a higher
concentration of antibody present. The median titers of
neonates for anti-HBe and anti-HBc were higher than
or equal to those of mothers, respectively (Table 3). Our
results mirror a similar report [25], which is because
placental transfer of IgG is an active process by means of
the binding of maternal IgG to neonatal Fc receptors in
the placenta [26].
Our present study further showed that in infants, ap-
proximately 88.1 HBsAg, 88.5 HBeAg and 64.3 % HBV-
DNA disappeared at the age of 8–12 months. This may
simply represent transplacental maternal (HBsAg and
HBeAg) non-infectious antigens rather than infectious
HBV particles replicating in the infants’ own bodies.
Alternatively, the immunoprophylaxis measures (HBIG
plus hepatitis B vaccine) administered to neonates, espe-
cially for those with low titer of HBV-DNA at birth, may
prevent part of the maternal-fetal transmission that oc-
curs during delivery. The appearance of these antigens
at birth may not be an indication that neonates are in-
fected with HBV in-utero as infection in-utero may
lead to fetal immuno tolerance to HBV and a chronic
hepatitis B carrying status [27, 28].
Our results show transplacental anti-HBe disappeared
in 80.9 % infants before 8-12 month of age, and new
anti-HBe antibodies were not produced in the immuno-
prophylaxis protected infants born to HBeAg-positive
mothers. In view of these findings, in-utero infection
may occur less frequently than previously speculated.
Transplacental anti-HBc can last a longer period of time
than anti-HBe in infants born to HBsAg-carriermothers.
Anti-HB was detected in about half of the infants in this
Table 5 Serum testing results in immunoprophylaxis failure infants and their mothers
Group No. Mother Infant
At birth 8–12 months
HBsAg HBeAg HBV-DNA HBsAg HBeAg HBV-DNA HBsAg HBeAg HBV-DNA
1 a 2685 1024 8.2 8537 897.9 6.2 968.2 1626 8.7
b 364.5 729.8 8.1 560.3 44.74 6.5 360.5 1516 7.4
c* 3319 447.9 8.2 6205 6.76 6.5 1647 1110 7.9
d* 1719 1762 7.6 1244 1771 8.5 901.1 1898 8.6
2 a 286.5 1367 6.5 122.3 22.08 3.8 256 900 7.4
b 98.13 305.6 7.6 6.74 138.2 3.9 391.1 878.1 8.0
c 1318.4 221.3 7.2 3.92 25.24 3.3 581.6 1220 7.1
d 47.8 27.6 6.5 5.13 9.02 4.3 2380 885.2 7.7
e* 1284 1226 7.6 3.71 11.51 3.8 980.3 1279 8.0
f* 3350 5020 7.7 55.72 + 3.2 2466 1256 7.5
3 a 379.6 961.4 6.9 2.97 12.25 — 378.8 565.1 7.6
b 971.6 9.707 7.4 4616 106.4 — 220 244.1 6.2
c 478.7 829.2 6.6 26.06 10.02 — 349.6 18.3 8.3
d 1419 813.9 6.8 1.39 108.2 — 3732 907.3 6.5
e 3255 785.1 6.6 0.48 11.44 — 4681 960.4 6.8
f* 1975 1316 7.3 17.66 + — 5967 1449 5.7
g* 2407 1299 7.9 1.0 14.09 — 25.03 897.1 4.6
The number labeled “*” represents UC and without “*” represents FV, HBsAg (COI), HBeAg (COI), HBV-DNA (log 10copies/mL); —: HBV-DNA < 500 copies/mL;
+: This index was positive for qualitative analysis according to previous assay sheet and not tested by quantitative analysis because of insufficient sample
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study at the age of 8–12 months. And it had previously
been reported to disappear before 24 months of age
[29]. Therefore, the sole presence of anti-HBe before 12
months of age with or without anti-HBc before 24 month
of age in immunoprophylaxis protected infants born to
HBsAg-carriermothers suggests the transplacental trans-
fer of maternal antibodies to the infants, and may not in-
dicate that the infants have experienced viral infection
in-utero.
Thus, these positive indices at birth that disappear
during follow-up are transferred from the mothers, ra-
ther than through HBV replication in the infants. This is
an important difference between infants with positive
HBV markers and adults who suffer from HBV infection.
Previously published opinions which state that HBsAg
and/or HBV-DNA positivity in neonates at birth should
be criteria for intrauterine infection [12–14] may have
failed to consider the fact that loss of HBV markers in
follow-up is inconsistent with intrauterine infection. Our
finding is consistent with a study by Papaevangelou V, et
al. [30], which reaches a similar conclusion that the pres-
ence of HBV-DNA in newborns may not represent HBV
infection.
Among the seventeen infants of immunoprophylaxis
failure, four may represent intrauterine infection, be-
cause in those infants HBV-DNA viral load was > 6
log 10copies/mL both at birth and at 8–12 months of
age. The results suggest that the neonates were likely
to be infected with HBV in utero, but this study cannot
demonstrate that infection definitely occurred in-utero,
because some newborns maybe exposed to large amount
of HBV during delivery, leading to high levels of HBV-
DNA at birth [31].
In six other infants, mean viral-loads of HBV-DNA
were significantly lower at birth than were their follow-
up viral loads. The HBV-DNA level of these six infants
(3.72 ± 0.17 log 10copies/mL) was similar to that of the
eighteen infants (3.48 ± 0.68 log 10copies/mL) whose
HBV-DNA was positive at birth and negative at follow-up
visits. Since those eighteen infants were able to clear the
virus after immunoprophylaxis, the six infants with low
level of HBV-DNA at birth might have been HBV positive
at birth with immunoprophylaxis failure. However, we
cannot completely rule out the possibility of these infants
being infected in the late stage of pregnancy.
Notably, there were seven neonates that tested HBV-
DNA negative at birth but found to be HBV-DNA positive
at 8–12 months of age, with six of them being formula
feed. For these six infants, transmission during breastfeed-
ing can be excluded. If an infant has received immunopro-
phylaxis, infection through breast milk is not considered
as a factor to put the child at risk of maternal-infant trans-
mission [18, 32]. Therefore, the findings suggest these
infants were more likely to have been infected during
delivery, but in-utero infection cannot be excluded when
HBV markers are negative at birth because in-utero infec-
tion that occur 1–2 weeks antepartum may have negative
HBV markers due to the relatively long period of incuba-
tion time of HBV infection.
In this study, 165 (42.9 %) were negative for HBsAg,
HBeAg and HBV-DNA both at birth and during follow-
up. These infants were followed at 8–12 months of age
after birth, when they have had a complete course of
vaccination and infants’ daily activities were mainly hap-
pened with their mothers, that is, there is almost no
chance of other HBV exposure. So apart from “acciden-
tal infection”, the possibility of inadequate immune re-
sponse and postpartum infection can be excluded. This
suggests that these infants did not become HBV infected
in utero or during delivery and remained infection-free
at follow-up, although it cannot be ascertained that
immunoprophylaxis was effective.
HBV markers, HBsAg, HBeAg and/or HBV-DNA, in
high risk infants at birth, disappeared at 8-12 months with
the loss rate of 88.1 %, 88.7 %, 64.3 %, respectively. Con-
versely, these markers, negative at birth, became positive
in a small number of infants during the follow-up period.
Therefore, positivity of HBV markers at birth cannot
universally be used to define in-utero or maternal-infant
transmission, and negativity for HBV markers cannot be
used to exclude maternal-infant transmission. The dy-
namic changes of viral load in HBV infected infants may
indicate the estimated possible infection period (Table 6),
but it is still impossible to definitively differentiate in-
utero infection from delivery infection. Therefore, mon-
itoring high-risk infants during follow-up is essential
for the determination of maternal-infant transmission.
We suggest that follow-up studies should be done at 8–
12 months age because the markers of both infection
(HBsAg) and immunity (anti-HBs) may develop after
immunization in this high risk population.
In this study, whether or not the specimens were col-
lected from neonates via the FV or the UC, a similar-
transplacental rate of acquisition and loss of each HBV
marker was noted both at birth and during the follow-
up period. The subgroup analysis confirmed the results’
reliability. The results also indicate that both UC and FV
Table 6 Tendency of infection periods among infants of
immunoprophylaxis failure
Group HBV-DNA viral load Intrauterine infection Delivery infection
At birth Follow up
1(a-d) higha high +++ +
2(a-f) lowb high ++ ++
3(a-g) negative high + +++
More “+” means the degree of possibility is more likely
aHBV-DNA > 6 log 10copies/mL
bHBV-DNA <4 log 10copies/mL
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blood drawing share the same feasibility. So, compared
with FV, UC drawing might be a better way of blood
drawing for neonates by its characteristics of compara-
tively easy, timely, safe and acceptable by parents.
Passive-active prophylaxis has been demonstrated to
be effective in preventing HBV infection in most of in-
fants born toHBsAg-carrier mothers. However, HBV
maternal-infant transmission still occurs after passive-
active immunization. This study suggests that the major-
ity infants with immunoprophylaxis failure were infected
with HBV during delivery. It may be more effective to
give neonates a higher titer of HBIG in reducing the rate
of perinatal transmission. It is reported that the efficacy
of monoclonal antibody of HBIG was 100 times the titer
of HBIG available now with the same dosage [33]. It
may be worthwhile to try this antibody in preventing
maternal-infant transmission, but this work needs fur-
ther investigation.
It’s also possible that a small part of immunoprophy-
laxis failure in infants occurred due to in-utero infection.
Administration of antiviral therapy to lower the maternal
serum HBV-DNA levels may reduce the rate of intra-
uterine infection. Preliminary studies have suggested that
nucleoside analogues against HBV infection, (lamivudine
or telbivudine) may reduce HBV intrauterine infection
[34, 35], but there is still not enough evidence regarding
the safety and effectiveness of this treatment in pregnant
women, especially for symptom-free hepatitis B carriers.
Large clinical trials are needed to further investigate the
efficacy of anti-HBV therapy for pregnant women in pre-
venting HBV maternal-infant transmission in pregnant
women.
Study limitations: First, there was only one follow-up
time point, from which it is impossible to estimate either
when HBV markers became undetectable or when these
markers became detectable. Further studies are needed to
explore the exact modes of HBV maternal-infant trans-
mission, which will inform the implementation of more
effective measures to prevent perinatal infection. Second,
this study did not perform molecular characterization of
the HBV isolated from the mothers compared to the iso-
lates from the neonates. Differing HBV viral strains may
have been a confounding factor in the vertical transmis-
sion and immunoprophylaxis failure together with or
irrespective of viral load. This is also a subject of further
study.
Conclusions
This prospective study described HBV maternal-infant
transmission in a high risk group of maternal-infant pairs
in China and analyzed the possible periods of transmission
based on serological characteristics of matched maternal-
infant samples. HBV maternal-infant transmission still
occurred after passive-active immunization. This study
provided evidence that the placental barrier can partly
prevent maternal HBV markers from passing through to
fetus; that fetuses got their maternal HBV markers do not
represent true infection of HBV; the dynamic changes in
viral load from birth through the follow-up period could
be referred to for the diagnosis of infection period; in-
utero infection may occur less frequently than previously
speculated. Above all, although even today, with sensitive
testing, the exact mode of maternal-infant transmission,
in utero, at delivery or during the neonatal period, could
not be exactly differentiated, but what seems certain is
that serological positive markers of HBVin femoral vein
blood or umbilical cord blood should not be evidence of
in-utero infection among neonates.
Abbreviations
FV, femoral venous; HBIG, hepatitis B immunoglobulin; HBV, hepatitis B virus;
IQR, inter quartile range; UC, umbilical cord.
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